HUP0300236A3 - Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation - Google Patents

Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation

Info

Publication number
HUP0300236A3
HUP0300236A3 HU0300236A HUP0300236A HUP0300236A3 HU P0300236 A3 HUP0300236 A3 HU P0300236A3 HU 0300236 A HU0300236 A HU 0300236A HU P0300236 A HUP0300236 A HU P0300236A HU P0300236 A3 HUP0300236 A3 HU P0300236A3
Authority
HU
Hungary
Prior art keywords
incidence
preparation
reducing
fatty acids
polyunsaturated fatty
Prior art date
Application number
HU0300236A
Other languages
English (en)
Original Assignee
Univ Tennessee Res Corp Knoxvi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0300236(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/943,576 external-priority patent/US6080787A/en
Application filed by Univ Tennessee Res Corp Knoxvi filed Critical Univ Tennessee Res Corp Knoxvi
Publication of HUP0300236A2 publication Critical patent/HUP0300236A2/hu
Publication of HUP0300236A3 publication Critical patent/HUP0300236A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
HU0300236A 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation HUP0300236A3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80470097A 1997-02-21 1997-02-21
US82531497A 1997-03-28 1997-03-28
US08/943,576 US6080787A (en) 1997-02-21 1997-10-03 Methods for reducing the incidence of necrotizing enterocolitis
PCT/US1998/003235 WO1998036745A2 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis

Publications (2)

Publication Number Publication Date
HUP0300236A2 HUP0300236A2 (hu) 2003-06-28
HUP0300236A3 true HUP0300236A3 (en) 2003-09-29

Family

ID=27420004

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300236A HUP0300236A3 (en) 1997-02-21 1998-02-19 Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation

Country Status (24)

Country Link
US (1) US6306908B1 (hu)
EP (1) EP1039892B1 (hu)
JP (1) JP2001516343A (hu)
CN (1) CN1200701C (hu)
AT (1) ATE265207T1 (hu)
AU (1) AU732903B2 (hu)
BR (1) BR9807443A (hu)
CA (1) CA2281706C (hu)
DE (1) DE69823548T2 (hu)
DK (1) DK1039892T3 (hu)
ES (1) ES2219871T3 (hu)
HK (1) HK1034033A1 (hu)
HU (1) HUP0300236A3 (hu)
ID (1) ID22744A (hu)
IL (1) IL131126A (hu)
NO (1) NO994052L (hu)
NZ (1) NZ337039A (hu)
PL (1) PL343902A1 (hu)
PT (1) PT1039892E (hu)
RU (1) RU2199317C2 (hu)
SK (1) SK112399A3 (hu)
TR (1) TR199902023T2 (hu)
TW (1) TWI230607B (hu)
WO (1) WO1998036745A2 (hu)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121165A0 (en) * 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
DE19836339B4 (de) 1998-08-11 2011-12-22 N.V. Nutricia Kohlenhydratmischung
US20090274660A1 (en) * 1999-08-17 2009-11-05 Immunopath Profile, Inc. Pluripotent therapeutic compositions and uses thereof
US6596302B2 (en) * 2000-04-13 2003-07-22 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof
ES2424989T3 (es) * 2002-09-24 2013-10-10 Suntory Holdings Limited Composición que contiene ácido araquidónico solo o en combinación con ácido docosahexaenoico para potenciar las capacidades cognitivas en adultos
US7323206B1 (en) 2003-03-04 2008-01-29 B. Braun Medical Inc. Reagents and methods for all-in-one total parenteral nutrition for neonates and infants
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
CA2532489C (en) * 2003-06-23 2012-12-11 Nestec S.A. Infant or follow-on formula
MXPA05014190A (es) * 2003-06-24 2006-07-03 Univ Kansas Medical Center Formula para lactantes.
EP1660071A1 (en) * 2003-08-18 2006-05-31 Btg International Limited Treatment of neurodegenerative conditions
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
US8252769B2 (en) * 2004-06-22 2012-08-28 N. V. Nutricia Intestinal barrier integrity
EP1721611A1 (en) * 2005-04-21 2006-11-15 N.V. Nutricia Nutritional supplement with oligosaccharides for a category of HIV patients
RU2429718C2 (ru) * 2004-06-22 2011-09-27 Н.В. Нютрисиа Повышение целостности барьера у больных с вич
US7862808B2 (en) 2004-07-01 2011-01-04 Mead Johnson Nutrition Company Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB0504362D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
US7303745B2 (en) 2005-04-15 2007-12-04 Bristol-Myers Squibb Company Method for preventing or treating the development of respiratory allergies
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
MX2007013075A (es) * 2005-04-21 2008-01-11 Nutricia Nv Suplemento nutritivo para pacientes con vih.
BRPI0613274A2 (pt) 2005-05-23 2009-08-04 Massachusetts Inst Technology composições que contêm pufa e métodos de uso das mesmas
JP2007063219A (ja) * 2005-09-01 2007-03-15 Juntendo 新生児壊死性腸炎疾患予防剤
US20070166354A1 (en) 2005-10-26 2007-07-19 Bridget Barrett-Reis Method of reducing the risk of retinopathy of prematurity in preterm infants
US7829126B2 (en) 2005-10-26 2010-11-09 Abbott Laboratories Infant formulas containing docosahexaenoic acid and lutein
WO2007059431A1 (en) 2005-11-14 2007-05-24 The Trustees Of Columbia University In The City Of New York Use of an omega-3 lipid-based emulsion following ischemic injury to provide protection and recovery in human organs
AU2006327995B2 (en) * 2005-12-23 2012-09-13 N.V. Nutricia Infant nutritional compositions for preventing obesity
US20080003329A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Enriched infant formulas
US20080003330A1 (en) * 2006-06-30 2008-01-03 Ricardo Rueda Infant formulas for early brain development
US7867542B2 (en) * 2006-11-02 2011-01-11 Ach Food Companies, Inc. Non-flammable release composition
EP2200443B2 (en) 2007-09-17 2021-06-30 Cornell University Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
CN101896073B (zh) * 2007-10-09 2013-11-20 酶学技术有限公司 用于治疗胃肠道紊乱和促进肠道发育及成熟的脂质组合物
UY31410A1 (es) * 2007-10-30 2009-05-29 Composicion que comprende acidos grasos poliinsaturados y carbon vegetal activado
CN101909467B (zh) 2007-11-01 2013-04-24 恩兹默泰克有限公司 用于婴儿营养的脂质混合物
US8361534B2 (en) * 2007-12-20 2013-01-29 Abbott Laboratories Stable nutritional powder
AU2008343689A1 (en) * 2007-12-20 2009-07-09 Abbott Laboratories Stable nutritional powder
EP2100897A1 (en) 2008-01-30 2009-09-16 BNLfood Investments SARL Lecithin based composition and its use in food
WO2009096772A1 (en) * 2008-02-01 2009-08-06 N.V. Nutricia Composition for stimulating natural killer cell activity
US9737213B1 (en) * 2009-03-24 2017-08-22 Vioptix, Inc. Using an oximeter probe to detect intestinal ischemia
CN102368913A (zh) * 2009-04-01 2012-03-07 雀巢产品技术援助有限公司 降低肥胖的风险
TW201112967A (en) 2009-09-16 2011-04-16 Abbott Lab Dryblended nutritional powders
TW201121431A (en) 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
TWI492744B (zh) * 2009-12-04 2015-07-21 Abbott Lab 使用類胡蘿蔔素調節早產兒發炎症之方法
CN102665428A (zh) * 2009-12-08 2012-09-12 雀巢产品技术援助有限公司 含有益生菌和乳脂肪球膜组分的婴儿配方
ES2569241T5 (es) 2010-01-19 2019-09-11 Abbott Lab Una composición que comprende Lactobacillus rhamnosus HN001 y prebióticos para su uso en el tratamiento de la enfermedad pulmonar alérgica
CA2785523A1 (en) 2010-01-29 2011-08-04 Abbott Laboratories Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
CN102711524B (zh) 2010-01-29 2014-09-10 雅培制药有限公司 包含hmb钙的营养乳剂
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣hmb及可溶性蛋白質之實質上透明營養液
EP2397038A1 (en) 2010-06-21 2011-12-21 Abbott Laboratories Early programming of brain function through soy protein feeding
WO2012009426A1 (en) 2010-07-13 2012-01-19 Abbott Laboratories High tolerance infant formula including hydrolyzed protein
EP2422629A1 (en) 2010-08-23 2012-02-29 Abbott Laboratories Methods for enhancing cognition and/or memory using maltodextrins
WO2012027287A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Nutritional products including pea protein hydrolysates
DK2608681T3 (en) 2010-08-24 2015-10-19 Abbott Lab Nutritional products with improved organoleptic properties
ES2558112T3 (es) 2010-12-29 2016-02-02 Abbott Laboratories Productos nutricionales que incluyen un nuevo sistema lipídico que incluye monoglicéridos
US9539269B2 (en) 2010-12-31 2017-01-10 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
ES2667393T3 (es) 2010-12-31 2018-05-10 Abbott Laboratories Oligosacáridos de leche humana para modular inflamación
SG191394A1 (en) 2010-12-31 2013-08-30 Abbott Lab Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
SG191393A1 (en) 2010-12-31 2013-08-30 Abbott Lab Neutral human milk oligosaccharides to promote growth of beneficial bacteria
CN108420076A (zh) * 2010-12-31 2018-08-21 雅培制药有限公司 包含人乳低聚糖和长链多不饱和脂肪酸的营养型制剂以及其用途
BR112013016914A2 (pt) 2010-12-31 2019-09-24 Abbott Lab combinação simbiótica de probióticos e oligossacarídeos do leite humano para promover o crescimento de microbiota benéfica
EP2658399B2 (en) 2010-12-31 2024-02-28 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides for use in treating and/or preventing enteric rotavirus infection
ES2708924T3 (es) 2010-12-31 2019-04-12 Abbott Lab Procedimientos de uso de oligosacáridos de la leche humana para mejorar la salud respiratoria de las vías respiratorias
WO2013012989A2 (en) 2011-07-19 2013-01-24 The Trustees Of Columbia University In The City Of New York Method and system for production of hydrogen and carbon monoxide
ES2657744T3 (es) 2011-07-22 2018-03-06 Abbott Laboratories Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal
EP2750523A1 (en) 2011-08-29 2014-07-09 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
BR112014016310A8 (pt) 2011-12-29 2017-07-04 Abbott Lab métodos para reduzir a contaminação microbiana de composições nutricionais em pó produzidas por mistura a seco
WO2013101516A1 (en) 2011-12-29 2013-07-04 Abbott Laboratories Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using extracted genomic dna
US20150064220A1 (en) 2012-03-27 2015-03-05 Abbott Laboratories Methods for modulating cell-mediated immunity using human milk oligosaccharides
WO2013170189A1 (en) 2012-05-11 2013-11-14 Abbott Laboratories Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow
ES2572831T3 (es) 2012-09-14 2016-06-02 Abbott Laboratories Composiciones nutricionales para su uso en métodos para modular los niveles de corticosterona en individuos con estrés psicológico
ES2795665T3 (es) 2012-09-14 2020-11-24 Abbott Lab Procedimientos para aumentar la funcionalidad cerebral utilizando 2-fucosil-lactosa
EP2708146A1 (en) 2012-09-17 2014-03-19 Abbott Laboratories, Inc. Nutritional composition for pregnant women with a beneficial glucose and insulin profile
WO2014078544A1 (en) 2012-11-14 2014-05-22 Abbott Laboratories Compositions and methods for improving the long term safety of powdered infant formulas
WO2014099904A1 (en) 2012-12-17 2014-06-26 Abbott Laboratories Methods for enhancing motor function, enhancing functional status and mitigating muscle weakness in a subject
EP2934189B1 (en) 2012-12-18 2019-11-06 Abbott Laboratories Human milk oligosaccharides to ameliorate symptoms of stress
EP2745705A1 (en) 2012-12-18 2014-06-25 Abbott Laboratories Nutritional use of human milk oligosaccharides
WO2014100022A1 (en) 2012-12-18 2014-06-26 Abbott Laboratories Dietary oligosaccharides to enhance learning and memory
CA2894897C (en) 2012-12-20 2018-09-18 Abbott Laboratories Nutritional formulations using human milk oligosaccharides for modulating inflammation
EP2745708A1 (en) 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
SG11201507198PA (en) 2013-03-12 2015-10-29 Abbott Lab Composition comprising a multifunctional viscosity modifying agent
JP2016517438A (ja) 2013-03-15 2016-06-16 アボット・ラボラトリーズAbbott Laboratories 筋肉機能を維持し、改善する方法
EP2986163B1 (en) 2013-03-15 2017-04-19 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
CN105263321B (zh) 2013-03-28 2018-07-27 哥伦比亚大学纽约管理委员会 用omega-3甘油酯再灌注促进对用于移植的供体器官的保护
WO2014200961A1 (en) 2013-06-10 2014-12-18 Abbott Laboratories Methods and compositions for enhancing cognitive performance
WO2015048646A1 (en) 2013-09-30 2015-04-02 Abbott Laboratories Protein powder
CA2889312A1 (en) 2013-10-11 2015-04-16 Normanella Dewille Nutritional composition for pregnant women with a beneficial glucose and insulin profile
CN103558296B (zh) * 2013-10-18 2015-03-04 中国农业大学 一种基于脂肪酸检测的动物源性饲料原料鉴别方法
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术(上海)有限公司 Il-22二聚体在制备静脉注射药物中的应用
US10568896B2 (en) 2013-11-19 2020-02-25 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2888950A1 (en) 2013-12-24 2015-07-01 Abbott Laboratories Methods for treating, preventing, or reducing neuroinflammation or cognitive impairment
WO2015105981A2 (en) 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
SG11201608248YA (en) 2014-04-08 2016-10-28 Abbott Lab Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides
DE102015101273A1 (de) 2015-01-29 2016-08-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung von frühgeburtlichkeitsassoziierten Entwicklungsstörungen
US11510966B2 (en) 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
RU2665947C1 (ru) * 2017-07-13 2018-09-05 Атикат Магомедхановна Герейханова Способ лечения некротического энтероколита
JP7302032B2 (ja) 2019-06-07 2023-07-03 アボット・ラボラトリーズ 流動特性および消泡特性を有する栄養成分
MX2022012509A (es) 2020-04-06 2022-11-07 Abbott Lab Formulaciones nutricionales para modular citocinas inducidas por la respiracion.
CN112137998A (zh) * 2020-10-10 2020-12-29 上海交通大学医学院附属新华医院 一种活性成分在制备防治坏死性小肠结肠炎药物中的应用
WO2022177965A1 (en) 2021-02-16 2022-08-25 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2022226311A1 (en) 2021-04-23 2022-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function
WO2022266058A1 (en) 2021-06-14 2022-12-22 Abbott Laboratories Methods and compositions for treating gas
WO2023159093A1 (en) 2022-02-16 2023-08-24 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and bovine immunoglobulin
WO2024064327A1 (en) 2022-09-22 2024-03-28 Abbott Laboratories Human milk oligosaccharides for enhancing blood-brain barrier function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092121B1 (en) 1982-04-12 1987-12-16 Board Of Regents, The University Of Texas System Methods and compositions for treating gastro-intestinal ulcer diesease
US4670285A (en) 1982-08-06 1987-06-02 The University Of Toronto Innovations Foundation Infant formula
US4784861A (en) 1986-11-24 1988-11-15 Cca Industries, Inc. Weight-control formulation
US4950656A (en) 1987-02-17 1990-08-21 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US4918063A (en) * 1987-02-17 1990-04-17 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5043329A (en) 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
US5032585A (en) 1987-02-17 1991-07-16 Board Of Regents, The University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
US5000975A (en) 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5116819A (en) * 1989-05-05 1992-05-26 Clintec Nutrition Co. Enteral diet for patients with pulmonary disease
EP1092352A3 (en) 1991-01-24 2003-08-27 Martek Corporation Microbial oil mixtures and uses thereof
US5658767A (en) 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
DE4407939A1 (de) * 1993-03-15 1994-09-22 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von fett- und cholesterinreduzierten pulverförmigen Produkten auf Eibasis
FR2721481B1 (fr) * 1994-06-27 1996-09-06 Inst Rech Biolog Sa Nouvelles compositions diététiques à base de phospholipides et leur utilisation comme complément nutritionnel.
WO1996010922A1 (de) 1994-10-05 1996-04-18 Milupa Aktiengesellschaft Phospholipidhaltige fettmischung mit lcp-fettsäuren
JPH09201A (ja) * 1995-06-23 1997-01-07 Akikuni Yakida 炎症性腸疾患用食品
US5917068A (en) 1995-12-29 1999-06-29 Eastman Chemical Company Polyunsaturated fatty acid and fatty acid ester mixtures free of sterols and phosphorus compounds
US5790138A (en) 1996-01-16 1998-08-04 Monolithic System Technology, Inc. Method and structure for improving display data bandwidth in a unified memory architecture system

Also Published As

Publication number Publication date
PT1039892E (pt) 2004-09-30
IL131126A (en) 2003-04-10
DK1039892T3 (da) 2004-08-30
JP2001516343A (ja) 2001-09-25
NO994052D0 (no) 1999-08-23
RU2199317C2 (ru) 2003-02-27
TR199902023T2 (xx) 2001-09-21
CA2281706A1 (en) 1998-08-27
CN1269718A (zh) 2000-10-11
DE69823548D1 (de) 2004-06-03
WO1998036745A3 (en) 2002-10-03
WO1998036745A2 (en) 1998-08-27
ID22744A (id) 1999-12-09
EP1039892A2 (en) 2000-10-04
DE69823548T2 (de) 2005-02-24
US6306908B1 (en) 2001-10-23
ES2219871T3 (es) 2004-12-01
HUP0300236A2 (hu) 2003-06-28
BR9807443A (pt) 2000-04-25
AU6176998A (en) 1998-09-09
SK112399A3 (en) 2000-12-11
TWI230607B (en) 2005-04-11
IL131126A0 (en) 2001-01-28
NZ337039A (en) 2001-06-29
ATE265207T1 (de) 2004-05-15
EP1039892B1 (en) 2004-04-28
HK1034033A1 (en) 2001-10-12
AU732903B2 (en) 2001-05-03
CA2281706C (en) 2008-08-05
PL343902A1 (en) 2001-09-10
NO994052L (no) 1999-10-20
CN1200701C (zh) 2005-05-11

Similar Documents

Publication Publication Date Title
HUP0300236A3 (en) Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis and process for their preparation
EP0736545A3 (en) Ester of dextrin and fatty acids and its use
HUP9903703A3 (en) Process for preparing docosahexaenoic acid and docosapentaenoic acid
SG65631A1 (en) Preparation of acrylic acid and esters
IL117251A (en) Enzymatic process for obtaining polyunsaturated fatty acid triglyceride concentrates
AU2738497A (en) Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
EP1025842A4 (en) PREPARATION OF A CAPSULE CONTAINING AN UNSATURATED FATTY ACID OR A DERIVATIVE THEREOF, AND METHOD OF MANUFACTURE
GB9301629D0 (en) Formulations containing unsaturated fatty acids
PL331700A1 (en) Method of obtaining fatty acid esters
AU4564399A (en) Polyunsaturated fatty acids in plants
ZA9711159B (en) Immobilized enzyme and its use for the processing of triglyceride oils
PL331495A1 (en) Method of obtaining surface-acting sorbitane esters and fatty acids
AU4130597A (en) Use of essential fatty acids for the treatment and prevention of radiation damage to erythrocytes
GB9620248D0 (en) Esters of unsaturated fatty acids
AUPQ480399A0 (en) Unsaturated fatty acids and their uses in therapy
AU3776595A (en) Process for the hydrolysis of the triglycerides of polyunsaturated fatty acids
PL332853A1 (en) Method of obtaining alpha-alkoxy-alpha-trifluoromethyl-acrylacetic esters and acids
SI1039892T1 (en) Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis
ZA895758B (en) Polyunsaturated fatty acids
SG65781A1 (en) Process for the preparation of heteroarylcarboxylic amides and esters
IL116134A0 (en) Iminooxybenzylcrotonate esters their preparation and their use
GB9621293D0 (en) Formulations containing unsaturated fatty acids
IL123421A0 (en) Phenylacetic acids their preparation and compositions comprising them
AU3645195A (en) Modified polyunsaturated fatty acids
ZA981668B (en) Presentation of fatty acids

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees